<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699023</url>
  </required_header>
  <id_info>
    <org_study_id>239/07</org_study_id>
    <nct_id>NCT00699023</nct_id>
  </id_info>
  <brief_title>Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes</brief_title>
  <acronym>EZE</acronym>
  <official_title>Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ezetimibe in association with statins is
      more effective than statins alone on postprandial lipemia in type 2 diabetic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incremental AUC after a fat-rich meal of cholesterol concentration in chylomicron and VLDL fractions</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incremental AUC after a fat rich-meal of apo B48 concentration- marker of the number of intestinally derived lipoproteins- in chylomicron and VLDL</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting LDL concentration</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol/triglyceride ratio in postprandial chylomicrons and VLDL fractions.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial LDL size</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration and Composition of different lipoprotein subclasses in the fasting condition.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Postprandial Lipemia</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo + simvastatin tablets 20 mg/die six weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe tablets</intervention_name>
    <description>ezetimibe tablets 10 mg/die</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin tablets</intervention_name>
    <description>simvastatin tablets 20 mg/die</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes since at least two years

          -  Stable metabolic control (HbA1c&lt;8.0%) for at least six months on diet or diet+oral
             hypoglycemic drugs (insulin secretagogues or metformin), not to be changed during the
             study period.

          -  BMI&lt;30 kg/m2 and body weight stable during the last six months.

          -  Both sexes; only post-menopausal women.

          -  LDL-cholesterol &gt;130 mg/dl, plasma triglycerides &lt;400 mg/dl.

          -  No use of hypolipidemic drugs in the last three months.

        Exclusion Criteria:

          -  Patient with renal (serum creatinine &gt;1.5 mg/dl) or hepatic (serum transaminases
             &gt;three times upper normal values) impairment.

          -  Patients with history of cardiovascular disease.

          -  Pre-menopausal women.

          -  Any other acute or chronic degenerative disease.

          -  Anemia (Hb&lt;12 g/dl).

          -  Uncontrolled blood pressure.

          -  Use of any drugs able to interfere with the study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriele Riccardi, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Clinical and Experimental Medicine, Federico II University Hospital, Naples, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical and Experimental Medicine, Federico II University Hospital,</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Rivellese AA, De Natale C, Di Marino L, Patti L, Iovine C, Coppola S, Del Prato S, Riccardi G, Annuzzi G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. J Clin Endocrinol Metab. 2004 May;89(5):2153-9.</citation>
    <PMID>15126535</PMID>
  </reference>
  <reference>
    <citation>Annuzzi G, De Natale C, Iovine C, Patti L, Di Marino L, Coppola S, Del Prato S, Riccardi G, Rivellese AA. Insulin resistance is independently associated with postprandial alterations of triglyceride-rich lipoproteins in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2397-402. Epub 2004 Sep 30.</citation>
    <PMID>15458975</PMID>
  </reference>
  <reference>
    <citation>Davidson MH, Toth PP. Combination therapy in the management of complex dyslipidemias. Curr Opin Lipidol. 2004 Aug;15(4):423-31. Review.</citation>
    <PMID>15243215</PMID>
  </reference>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2008</study_first_posted>
  <last_update_submitted>November 3, 2009</last_update_submitted>
  <last_update_submitted_qc>November 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Angela A. Rivellese, MD</name_title>
    <organization>Department of Clinical and Experimental Medicine Federico II University Naples</organization>
  </responsible_party>
  <keyword>postprandial lipemia</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>ezetimibe</keyword>
  <keyword>hypercholesterolemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

